In this study, tirzepatide persistence (73.3%) using a 45-day treatment gap was similar to that of dulaglutide (69.2%71.9%) and greater than that of semaglutide (59.2%62.2%) at 6 months reported previously in claims-based studies in patients with T2D newly initiating GLP-1 therapy [47, 48]
However, the most suitable treatment depends on individual factors such as medical history, medication tolerance, and clinician guidance
The dual mechanism advantage Understanding why tirzepatide produces superior results requires a quick look at how these medications actually work
In addition to a formulation of semaglutide for once-weekly subcutaneous administration [4], a tablet formulation of semaglutide has also been developed, where semaglutide is co-formulated with the absorption enhancer sodium N -(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), thereby providing the first GLP-1 receptor agonist to be administered orally (oral semaglutide)

Drug name and brand name (both generic and brand name where applicable) Dosage administered (in milligrams, milliliters, or units as appropriate) Route of administration (intravenous, intramuscular, subcutaneous, etc.) NDC number (National Drug Code, 11-digit format) NDC units and the appropriate unit qualifier (UN for units, ML for milliliters, GR for grams, F2 for international units) Medical necessity documentation (diagnosis code linking the drug to the condition treated) FDA approval status of the drug, if applicable Purchase invoice or acquisition cost (many payers, and any drug bought under a 340B agreement, require the wholesale invoice showing what the practice actually paid) For compounded drugs, the American Academy of Ophthalmologys coding guidance is specific: list each component drug and its dosage in the descriptor field, and list all NDCs for each drug administered in item 24 of the CMS-1500

A hub that embraces feedbackcollecting suggestions and publishing changelogsdemonstrates accountability